SinoMab BioScience Limited (3681.HK) Comparison with companies in other sectors?

SinoMab BioScience Limited has a share price of 1.19B. You can analyze SinoMab BioScience Limited (3681.HK) competitors across different market sectors through stock heatmaps.

What are 3681.HK's NET and operating margins?

SinoMab BioScience Limited (3681.HK) operating margin is around -79.92, and net profit margin is approximately -91.38 as of the latest reports.

In what way does 3681.HK's earnings per share (EPS) trend reflect its financial momentum?

SinoMab BioScience Limited (3681.HK) EPS is -0.19 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for SinoMab BioScience Limited is -16.42, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for SinoMab BioScience Limited?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for SinoMab BioScience Limited like P/E which is -16.65, P/B which is 15.98, and PEG which is -1.72. Compare them with sector averages to evaluate if the stock is priced fairly.

SinoMab BioScience Limited

3681.HK•HKSE

Healthcare

Biotechnology

HK$3.40

HK$0.20(6.25%)

SinoMab BioScience Limited (3681.HK) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-0.19

P/E Ratio

-16.42

ROE

-0.79%

Net Margin

-91.38%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$3.72B

Shares OutstandingTotal number of shares issued

$1.19B

Book Value/ShareNet worth per share

$0.18

Revenue/ShareAnnual revenue per share

$0.002

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.19

Net MarginNet income as percentage of revenue

-9138.25%

Operating MarginOperating income as percentage of revenue

-7992.40%

ROEReturn on shareholders' equity

-78.81%

ROAReturn on total assets

-24.58%

ROCEReturn on capital employed

-29.46%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.12

Cash/ShareCash and equivalents per share

$0.10

FCF YieldFree cash flow as percentage of market cap

-3.83%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for 3681.HKFinancial Ratios Analysis details for 3681.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 3681.HKSector Benchmarking details for 3681.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for SinoMab BioScience Limited Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of SinoMab BioScience Limited. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account SinoMab BioScience Limited's unique business strengths and challenges.

Key Financial Metrics for SinoMab BioScience Limited

For SinoMab BioScience Limited, essential financial indicators include EPS -0.19, PE -16.42, and ROE -0.79. These key ratios reveal insights into SinoMab BioScience Limited's profitability, valuation, and operational health. Understanding these metrics enables you to compare SinoMab BioScience Limited with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of SinoMab BioScience Limited

Metrics like Net Margin -9138.25% and ROA -24.58% shed light on how well SinoMab BioScience Limited is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether SinoMab BioScience Limited can sustain its operations and continue growing in the future.

Valuation and Market Position of SinoMab BioScience Limited

Using ratios such as P/B Ratio 15.98 and PEG Ratio -1.72, investors can assess whether SinoMab BioScience Limited is appropriately valued based on its financials and growth potential. These figures, combined with SinoMab BioScience Limited's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for SinoMab BioScience Limited

Financial health indicators, such as Debt/Equity Ratio 2.50 and Cash Flow $-0.12, provide a snapshot of SinoMab BioScience Limited's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like SinoMab BioScience Limited, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for SinoMab BioScience Limited

Investing in SinoMab BioScience Limited based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at SinoMab BioScience Limited focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;